Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'
A federal judge on Friday dismissed Amgen’s lawsuit against Colorado's drug affordability board and its decision to place a price cap on the company's blockbuster autoimmune drug.
Amgen (AMGN) closed at $311.55 in the latest trading session, marking a +1.5% move from the prior day. This move outpaced the S&P 500's daily gain of 0.55%. Elsewhere, the Dow gained 1.01%, while ...
Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...
Shares of Amgen and IBM are posting strong returns Monday morning, sending the Dow Jones Industrial Average into positive territory. The Dow is trading 113 points (0.3%) higher, as shares of Amgen and ...
Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...
TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback